Clinical Trial

Adjuvant Tebentafusp in High Risk Ocular Melanoma

Study acronym: ATOM
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
At least 50% of patients with high-risk primary uveal melanoma will develop a recurrence following treatment of the primary tumour. Observation is currently the standard of care in the non-metastatic setting. Tebentafusp is the first agent proven to improve overall survival in patients with metastatic uveal melanoma in a randomized trial. Based on the results in the advanced setting, it is hypothesized that treatment with tebentafusp may reduce the risk of development of disease recurrence.
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2024-02-06; most recent amendment 2026-06-29.
Status change: Not Yet Recruiting → Recruiting 2024-11-27
Trial Details
NCT Number NCT06246149
Lead Sponsor European Organisation for Research and Treatment of Cancer - EORTC
Collaborators: Northwell Health, Immunocore Ltd
Conditions Uveal Melanoma
Enrollment 290 participants
Start Date 2024-11-11
Primary Completion 2032-11 (estimated)
Study Completion 2032-11 (estimated)
Updated on ClinicalTrials.gov 2026-06-30